Category: Rosacea

Topical Alpha-Agonist Therapy for Persistent Facial Erythema of Rosacea and the Addition of Oxmetazoline to the Treatment Armamentarium: Where Are We Now?

by James Q. Del Rosso, DO, FAOCD, FAAD Dr. Del Rosso is Research Director at JDR Dermatology Research, Las Vegas, Nevada and at Henderson Dermatology Research in Henderson, Nevada; is Adjunct Clinical Professor (Dermatology) at ableouro University Nevada, Las Vegas, Nevada; and practices Dermatology and Cutaneous Surgery at Thomas Dermatology in Las Vegas, Nevada. J


The Burden of Illness of Erythematotelangiectatic Rosacea and Papulopustular Rosacea: Findings From a Web-based Survey

aJames Q. Del Rosso, DO, FAOCD, FAAD; bEmil A. Tanghetti, MD; cHilary E. Baldwin, MD; dDavid A. Rodriguez, MD; eIlia L. Ferrusi, PhD aJDR Dermatology Research/Thomas Dermatology, Las Vegas, Nevada bThe Center for Dermatology and Laser Surgery, Sacramento, California cThe Acne Treatment and Research Center, Morristown, New Jersey dDermatology Associates and Research, Coral Gables, Florida;


Rosacea, Reactive Oxygen Species, and Azelaic Acid

by David A. Jones, MD, PhD Department of Dermatology, Brigham and Women’s Hospital, Boston, Massachusetts Abstract Rosacea is a common skin condition thought to be primarily an inflammatory disorder. Neutrophils, in particular, have been implicated in the inflammation associated with rosacea and mediate many of their effects through the release of reactive oxygen species. Recently,